NASDAQ:GTXI - GTx, Inc.
$0.94
 $-0.02
-2.12%
1:45PM EDT
2019-02-15
GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  GTXI     avg for
industry  
  avg for
sector  
42 stocks weight:  25. 16   0. 00   0. 00  
42 stocks rank:  3. 48 K 1. 86 K 1. 09 K
# analyst opinions:  2. 00   14. 92   14. 43  

quick ratio:  4. 09   5. 37   1. 81  
current ratio:  4. 31   5. 69   2. 19  

target price low:  1. 50   88. 97   117. 82  
target price avg:  1. 75   115. 19   141. 96  
target price high:  2. 00   143. 40   163. 16  
1-yr high:  25. 24   124. 30   142. 77  
last close:  0. 96   101. 85   127. 84  
50-day avg:  1. 01   98. 27   122. 46  
200-day avg:  9. 95   99. 72   122. 70  
1-yr low:  0. 75   78. 19   100. 16  
volume:  116. 92 K 2. 38 M 4. 64 M
50-day avg volume:  291. 44 K 3. 31 M 4. 94 M
200-day avg volume:  881. 73 K 3. 23 M 4. 28 M

1-day return:  -2. 04 % 0. 22 % 0. 48 %
this week return:  -3. 03 % 1. 77 % 2. 01 %
12-wk return:  -34. 25 % 6. 56 % 3. 33 %
52-wk return:  -93. 11 % -2. 23 % 14. 35 %

enterprise value (EV):  -14. 04 M 55. 17 B 104. 51 B
market cap:  23. 10 M 49. 01 B 96. 46 B
EBITDA:  -42. 83 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  0. 33   -91. 79   2. 29  
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -42. 28 M 2. 37 B 3. 58 B

shares outstanding:  24. 05 M 607. 99 M 1. 22 B
shares:  14. 85 M 605. 53 M 1. 15 B
shares short:  2. 32 M 11. 62 M 12. 55 M
shares short prior month:  2. 74 M 11. 95 M 13. 44 M
short ratio:  5. 51   4. 82   3. 10  
short % of float:  21. 71 % 6. 19 % 2. 82 %
total cash/share:  1. 58   12. 02   11. 46  
total cash:  38. 07 M 7. 41 B 7. 37 B
free cash flow:  -23. 98 M 95. 99 M 2. 04 B
operating cash flow:  -39. 46 M 164. 74 M 3. 04 B

book value:  1. 29   14. 43   28. 26  
price/book:  0. 75   -1. 57   -2. 97  
gross profits:  -21. 47 M 8. 28 B 18. 09 B
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  -92. 27 % --- ---
1-yr mean volatility:  -0. 29 % 0. 01 % 0. 06 %

1-yr EPS:  -1. 86   3. 03   4. 09  
forward EPS:  -0. 84   4. 33   6. 99  
P/E:  -0. 52   6. 11   26. 91  
forward P/E:  -1. 18   8. 38   10. 48  
PE/G:  0. 01   0. 37   5. 61  
growth:  -54. 52 % 683. 72 % 104. 79 %
earnings high:  -0. 14   1. 27   1. 66  
earnings avg:  -0. 22   1. 01   1. 53  
earnings low:  -0. 29   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -55. 75 % -3. 27 % 3. 81 %
return on equity:  -109. 06 % 107. 48 % 27. 82 %

beta (1yr vs S&P500):  1. 49   1. 21   0. 93  
sharpe (1yr):  -0. 57   0. 06   0. 98  

held % insiders:  52. 97 % 6. 46 % 3. 21 %
held % institutions:  21. 92 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : GTXI
.        + 0 =             0 :: INITIAL WEIGHT
.  + 270.263 =       270.263 :: inverse volume-to-price addition
.  + 178.242 =       448.505 :: spline projection addition
.  - 214.944 =        233.56 :: poor performance penalty
.    x 0.424 =        99.082 :: one-year gains+dividend factor
.    x 3.779 =       374.435 :: 13 weeks' performance factor
.    x 1.492 =        558.84 :: industry recommendation factor
.    x 0.994 =       555.725 :: return on assets factor
.    x 0.989 =       549.664 :: return on equity factor
.    x 2.758 =      1515.806 :: current ratio factor
.     x 1.15 =       1743.78 :: quick ratio factor
.    x 1.087 =      1895.424 :: short ratio factor
.    x 2.007 =      3804.987 :: price-to-book factor
.    x 5.645 =     21480.166 :: EBITDA multiple factor
.    x 2.174 =     46702.266 :: P/E weight
.    x 2.209 =    103163.397 :: PE/G factor
.    x 1.581 =    163075.614 :: beta factor
.    x 0.574 =     93669.119 :: sharpe factor
.     x 1.81 =    169570.392 :: target low factor
.    x 1.302 =    220845.513 :: target mean factor
.    x 1.104 =    243831.843 :: target high factor
.    x 1.066 =    259830.335 :: industry 12-weeks return
.    x 0.999 =    259503.112 :: overall "drift" factor
.    x 0.996 =    258466.544 :: largest single-day jump factor
.    x 0.062 =     15935.052 :: low price factor
.      x 1.0 =     15936.122 :: factor hist industry gain for week 06
.   cubeRoot =        25.165 :: reduced for readability
.                     25.165 :: FINAL WEIGHT for NASDAQ:GTXI


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org